{"entity":{"id":"portec-3","kind":"trial","name":"PORTEC-3","aka":[],"tldr":"Adding chemotherapy to radiation after surgery helped women with high-risk endometrial cancer, especially those whose tumours have a broken p53 gene.","summary":"5-year OS 81.4% vs 76.1% (HR 0.70) and failure-free survival 76.5% vs 69.1% in the updated analysis (Lancet Oncology 2019); the benefit was largest in stage III and serous cancers. Molecular analysis (de Boer/León-Castillo, JCO 2020) showed strong benefit in p53-abnormal tumours and none in POLE-mutated tumours, the basis for molecular-class-directed adjuvant therapy now tested in RAINBO.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT00411138","url":"https://clinicaltrials.gov/study/NCT00411138"},{"label":"Lancet Oncology 2019","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30395-X/fulltext"}],"tags":[],"related":[],"cancers":["endometrial","endometrial-p53-abnormal","endometrial-pole-ultramutated","endometrial-nsmp"],"sections":[],"technologies":["imrt-igrt","cytotoxic-chemotherapy","brachytherapy"],"targets":["tp53"],"drugs":[],"companies":["trog"],"institutions":[],"pathways":[],"terms":["endometrial-molecular-classes"],"trials":[],"people":["carien-creutzberg"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00411138","phase":"3","setting":"High-risk early or stage III endometrial cancer after surgery: chemoradiation + 4 cycles chemotherapy vs pelvic radiotherapy alone","sponsor":"Dutch Gynaecological Oncology Group","result":"5-year OS 81.4% vs 76.1% (HR 0.70); benefit concentrated in p53-abnormal disease.","started":"2006-11-23","startedType":"actual","yearReported":2018,"enrolled":660,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival at 5 years","unit":"%","arms":[{"name":"Chemoradiation + chemotherapy","n":330,"value":81.4},{"name":"Radiotherapy alone","n":330,"value":76.1}],"hr":0.7,"ci":[0.51,0.97],"source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30395-X/fulltext"}],"replication":"GOG-258 (chemoradiation vs chemotherapy alone) found no RFS difference, so the incremental value of radiation remains debated."},"route":"/trials/portec-3/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/"},{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"company":[{"id":"trog","kind":"company","name":"TROG Cancer Research","route":"/companies/trog/"}],"term":[{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/"}],"person":[{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","route":"/people/carien-creutzberg/"}],"idea":[{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/"}],"paper":[{"id":"paper-portec-3-molecular-leon-castillo-jco-2020","kind":"paper","name":"Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group","route":"/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/"},{"id":"paper-portec-3-lancet-oncol-2018","kind":"paper","name":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","route":"/key-papers/paper-portec-3-lancet-oncol-2018/"}],"roadmap":[{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/"}]}}